The historical & continuing roles of glucocorticoids in the treatment of RA are discussed.Â
The ACR Launches Rheumatoid Arthritis Measures Toolkit
The new resource offers standardized outcome measures for providers who treat patients with RA, as well as training materials for medical staff to guide accurate and efficient data collection. It also includes video tutorials and sample workflows for different EHR systems.
A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA
Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…
Methotrexate Shortage: Why It’s Happening & Potential Solutions
In recent months, many rheumatologists and rheumatology professionals have noted issues related to obtaining supplies of injectable and oral methotrexate for their patients with rheumatoid arthritis (RA). A conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), methotrexate is available as both oral tablets and as a subcutaneous injection for the treatment of RA and other autoimmune diseases.1…
RA Disease Activity & Alcohol Consumption Habits
Past studies have suggested that patients with rheumatoid arthritis (RA) who consume a moderate amount of alcohol may experience lower disease activity and higher quality of life than non-drinkers. In this study, Alfredsson, et al. confirmed earlier studies’ claims that alcohol consumption reduces disease activity in a dose-dependent manner, and also indicated that patients who stopped drinking post-baseline experienced worsened disease activity, more pain and a lower quality of life.
The Effect of Upadacitinib on Bone Erosion in Patients with RA
Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
Peresolimab Promising for RA
Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.
JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
Anti-P. copri Antibody Responses in Patients with RA
Background & Objectives Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with immune responses to the patient’s own antigens and characterized by inflammation and substantial joint destruction. Prevotella copri, a gut commensal bacterium, has been reported to be an immune-relevant organism in individuals with RA. This study sought to evaluate antibody responses to anti-P….
Diet May Help Reduce Inflammation in RA
In a small study, an anti-inflammatory diet helped reduce pain and swelling in a subset of people with rheumatoid arthritis (RA). Diet changes are complementary to standard treatment. Diet-related research can be challenging, but many patients with RA are motivated to try healthy changes.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 30
- Next Page »